Neumora Therapeutics, INC 10-Q quarterly reports

Neumora Therapeutics disclosed its Q2 2026 financial results, highlighting reduced operating expenses but also substantial accumulated deficit and ongoing concerns about its ability to continue as a going concern.

Neumora Therapeutics reported continued net losses in Q3 2025, a significant reduction in cash, and a major setback with its lead candidate navacaprant failing its Phase 3 primary endpoint.

Neumora Therapeutics reports an increased net loss and higher cash burn for the first half of 2025, securing a new $125 million term loan to extend its operational runway amidst ongoing clinical trials and a class action lawsuit.

Neumora Therapeutics announces its Q1 2025 financial results, detailing operating expenses, liquidity, and progress in its clinical development programs, including navacaprant and NMRA-511.

Neumora Therapeutics reports a net loss of $72.5 million for the third quarter of 2024, with ongoing clinical trials and research and development activities.

Neumora Therapeutics, a clinical-stage biopharmaceutical company, released its second quarter 2024 financial results, highlighting ongoing clinical trials and financial position.

Neumora Therapeutics reports a net loss of $53.7 million for the first quarter of 2024, while advancing its clinical programs, including the Phase 3 KOASTAL program for navacaprant.